Second Annual 
Huntington Disease Clinical Research Symposium

Organized by the Huntington Study Group
Saturday, November 15, 2008
8:00a.m. - 1:30p.m.
TradeWinds Island Hotel
St. Pete Beach, Florida 33706 U.S.A.

Huntington disease (HD), a devastating disease that robs people of their mobility, intellect, and sanity, has resisted attempts at treatment since it was first recognized in 1872 as a distinct genetic ailment.  Now, some 135 years later, clinical research into treatments that might alleviate symptoms and/or modify the disease are finally producing glimmers of hope for patients and families affected by the disease.

In recognition of the emerging focus on patient-oriented research, the Huntington Study Group (HSG), comprised of clinical investigators from the United States, Europe, and Australia, will convene the Second Annual Huntington Disease Clinical Research Symposium, to be held on Saturday morning, November 15, 2008 at the TradeWinds Island Hotel in St. Pete Beach, Florida. 

The Symposium will feature keynote addresses by:

• Charles Sabine, British NBC News Correspondent, who has a special interest in HD

• Russell Katz from the Food and Drug Administration (FDA), who will speak on pathways forward in treatments for manifest and pre-manifest HD patients

• A presentation by Lewis Maltby, President of the National Workrights Institute, on the recently enacted Genetic Information Nondiscrimination Act (GINA) legislation  

In addition to these keynote addresses, clinical scientists will be presenting their original research on relevant topics of interest to the HD community today.

The symposium is open to the HD community, the public and the press. Pre-registration by October 31st is free. On-site registration is $25.00 and is payable by cash or check at the event.